2nd Annual Central Africa IeDEA regional meeting (Burundi)

第二届中部非洲 IeDEA 区域年度会议（布隆迪）

• 批准号: 9011620
• 负责人: Kathryn M. Anastos
• 金额: $ 9.71万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-03-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9011620
• 关键词: Acquired Immunodeficiency Syndrome; Affect; Africa; Africa South of the Sahara; African; African American; Age; Aging; Behavioral; Burundi; CD4 Lymphocyte Count; CD4 Positive T Lymphocytes; Cameroon; Cardiovascular Diseases; Caring; Cause of Death; Central Africa; Characteristics; Chronic; Clinic; Clinical; Clinical Data; Clinical Sciences; Collaborations; Comorbidity; Conflict (Psychology); Country; Data; Data Analyses; Data Set; Disease; Disease Progression; Effectiveness; Enrollment; Ensure; Epidemiology; Europe; Exposure to; Fostering; Genetic; Government; Guidelines; HIV; HIV Infections; Health; Immunologics; Incidence; Individual; Intermediate Variables; Investigation; Kidney; Knowledge; Leadership; Malaria; Malignant Neoplasms; Metabolic; Methods; Modeling; Monitor; Morbidity - disease rate; Nutritional status; Office of Administrative Management; Outcome; Patients; Pattern; Persons; Policies; Policy Maker; Pregnancy; Prenatal care; Prevention; Process; Productivity; Public Health; Publications; Recording of previous events; Regimen; Reproductive Health; Research; Research Infrastructure; Research Support; Resources; Role; Rural; Rwanda; Services; Source; Specimen; Staging; System; Technology; Therapeutic; Time; Toxic effect; Tuberculosis; Ursidae Family; Vertical Disease Transmission; Viral Load result; Weight Gain; Woman; Work; antiretroviral therapy; burden of illness; care systems; clinical epidemiology; clinical phenotype; data management; design; electronic data; experience; flexibility; follow-up; implementation science; improved; innovation; interest; meetings; mortality; neoplasm registry; programs; reproductive; response; sex; skills; social stigma; success; technology development; translational study; treatment adherence; treatment program

Form Approved Through 6/30/2012 Department of Health and Human Services Council; 05/2011 r>..i~<:. '-(gaith Services PI: ANASTOS, KATHRYN M 1 2 1 6 1 5 3 7 application 1 U01 AI096299-01 AIDS/EXPED r length restrictions indicated. Dual:CA,HD Received: 11/12/2010 IRG: ZAI1 SRC(99) 1. TITLE OF PROJECT (Do not exceed 81 characters, including spaces a< Central Africa leDEA 2. RESPONSE TO SPECIFIC REQUEST FOR APPLICATIONS OR PROGRAM ANNOUNCEMENT OR SOLICITATION Q NO i ^ YES (If "Yes," state number and title) Number: RFA-AI-10-030 Title: International Epidemiologic Databases to Evaluate AIDS (leDEA) 3. PROGRAM DIRECTOR/PRINCIPAL INVESTIGATOR 3a. NAME (Last, first, middle) 3b. DEGREE(S) 3h. eRA Commons User Name Anastos, Kathryn Mary MD kanastos 3c. POSITION TITLE 3d. MAILING ADDRESS fS^reef, city, state, zip code) Professor of Medicine, Epidemiology and Population Health 3311 Bainbridge Avenue 3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT Bronx, NewYork 10467 Department of Medicine 3f. MAJOR SUBDIVISION Dept. of Epidemiology and Population Health 3g. TELEPHONE AND FAX (Area code, number and extension) E-MAIL ADDRESS: TEL: [phone] FAX: [e-mail] HUMAN SUBJECTS RESEARCH 4a. Research Exempt If "Yes," Exemption No. S No n Yes 13 No n Yes 4b. Federal-Wide /^surance No. 4c. Clinical Trial 4d. NIH-defined Phase III Clinical Trial ISI No D Yes Kl No n Yes 5. VERTEBRATE ANIMALS S No D Yes 5a. Animal Welfare Assurance No. DATES OF PROPOSED PERIOD OF COSTS REQUESTED FOR INITIAL 8. COSTS REQUESTED FOR PROPOSED SUPPORT (month, day. vear—MM/DD/yY) BUDGET PERIOD PERIOD OF SUPPORT From Through 7a. Direct Costs ($) 7b. Total Costs ($) 8a. Direct Costs ($) 8b. Total Costs ($) 07/01/11 06/30/16 $1,570,965 $1,999,581 $8,017,667 9997639 9. APPLICANT ORGANIZATION 10. TYPE OF ORGANIZATION Name Albert Einstein College of Medicine Public: -^ · Federal Q State · Local Address ^ 300 Morris Park Avenue Private: -> ^ Private Nonprofit Bronx, NewYork 10461 For-profit: -> CH General CH Small Business I I Woman-owned CH Socially and Economically Disadvantaged 11. ENTITY IDENTIFICATION NUMBER 113-1624225A2 DUNS NO. 110521739 Icong. District NY-007 12. ADMINISTRATIVE OFFICIAL TO BE NOTIFIED IF AWARD IS MADE 13. OFFICIAL SIGNING FOR APPLICANT ORGANIZATION Name Mr. Robert Ness Name Allen M. Spiegel, MD Title Associate Director for Grant Accounting Title Dean Address 1300 Morris Park Avenue Address ^gQQ Morris Park Avenue, Bronx, NY 10461 Bronx, New York 10461-1602 Tel: [phone] FAX: [phone] E-Mail: aorrn(gaecom.yu.edu 14. APPLICANT ORGANIZATION CERTIFICATION AND ACCEPTANCE: I certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties. PHS 398 (Rev. 6/09) Face Page Tel: [phone] FAX: [phone] E-Mail: [e-mail] SIGNATURE OF OFFICIAL NAMED IN 13 DATE (Inink. "Per"signaturendtaccpdtable.) Form Page 1 Use only if preparing an application with Multiple PDs/Pls. See http://qrants.nih.qov/qrants/multi pi/index.htm for details. Contact Program Director/Principal Investigator (Last, First, Middle): A n a S t O S , K a t h r y n M a r y 3. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR 3a. NAME (Last, first, middle) Hoover, Donald R. 3c. POSITION TITLE Professor Se. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT Statistics and Biostatistics 3f. MAJOR SUBDIVISION Institute for Health, Health Care Policy and Aging 3g. TELEPHONE AND FAX (Area code, number and extension) TEL: [phone] FAX: [phone]. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR 3a. NAME (Last, first, middle) 3c. POSITION TITLE 3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT 3f. MAJOR SUBDIVISION 3g. TELEPHONE AND FAX (Area code, number and extension) TEL: FAX: 3. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR 3a. NAME (Last, first, middle) 3c. POSITION TITLE 3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT 3f. MAJOR SUBDIVISION 3g. TELEPHONE AND FAX (Area code, number and extension) TEL: FAX: 3. PROGRAM DIRECTOR / PRINCIPAL INVESTIGATOR 3a. NAME (Last, first, middle) 3c. POSITION TITLE 3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT 3f. MAJOR SUBDIVISION 3g. TELEPHONE AND FAX (Area code, number and extension) TEL: FAX: PHS 398 (Rev. 6/09) Face 3b. DEGREE(S) 3h. NIH Commons User Name PhD MPH drhoover 3d. MAILING ADDRESS (^Sfreef, city, state, zip code) 110 Frelinghuysen Road, Room 1107 New Brunswick, New Jersey E-MAIL ADDRESS: [e-mail] 3b. DEGREE(S) 3d. MAILING ADDRESS E-MAIL ADDRESS: 3b. DEGREE(S) 3d. MAILING ADDRESS E-MAIL ADDRESS: 3b. DEGREE(S) 3d. MAILING ADDRESS E-MAIL ADDRESS: Page-continued 3h. NIH Commons User Name (Street, city, state, zip code) 3h. NIH Commons User Name (Street, city, state, zip code) ·- · 3h. NIH Commons User Name (^Sfreef, city, state, zip code) Form Page 1-continued Program Director/Principal Investigator (Last, First, Middle): A n a S t O S , K a t h r y n M a r y PROJECT SUMMARY (See instnjctions): The promise of antiretroviral therapy (ART) to provide renewed health is now being realized for millions of Africans. As HIV care and treatment programs are implemented throughout Africa, careful monitoring of their effectiveness is of crucial importance, so that care and treatment resources can be deployed to optimal benefit. Immunologic and clinical responses to ART, retention in care, and behavioral components (e.g. treatment adherence) need to be elucidated and predictors of survival defined. The impact of HIV and ART on cancers in Africa is essentially undescribed, and interactions with major ambient comorbidities such as malaria are pooriy understood. We propose a new Central Africa leDEA (CA-leDEA), designed to optimize and augment scientific productivity and rapid, high-impact publications; we will 1.) Compile and manage secondary source patient-level data on a large volume of patients through a.) extraction from existing electronic data, or b.) new on-the-ground systems for efficient capture of clinical data in low-resource clinical settings; 2.) Develop a creative and flexible scientific process that fosters high throughput of many analyses of data to answer epidemiologic, operational and other HIV-related research questions, culminating in high- impact publications; and 3.) Develop capacity for independent research, data management, analysis and publication in each of the Central African countries over five to ten years, ensuring the sustainability of CA- leDEA. Our team brings a long history in the region of research productivity and operational success, as well as innovative IT development to support research, with complementary skills and experience to optimize the activities of CA-leDEA. Four of our partners are the implementers of HIV care services (i.e. the governments) and the fifth partner, WE-ACTx Rwanda, brings patient volume, research experience and special resources to investigate AIDS malignancies. We will develop an administrative and data management infrastructure that supports the implementation of epidemiologic and implementation science to answer key questions in HIV care and treatment in lower-resource settings, with integrated research teams in the US, Cameroon and Rwanda. RELEVANCE (See instructions): Sub-Saharan AFrica bears the greatest burden of HIV disease globally. Research to define clinical and epidemiologic predictors of treatment success is needed to guide clinicians caring for persons with HIV. In addition, implementation science can guide policy makers and program implementers on service delivery mechanisms to provide most efficient use of treatment resoures and the optimal gain to the public's health.

表格已于 2012 年 6 月 30 日批准 卫生与公众服务部 理事会； 05/2011 r>..i~<:. '-（gaith 服务 PI：ANASTOS、KATHRYN M 1 2 1 6 1 5 3 7 应用 1 U01 AI096299-01 艾滋病/急症 r 表示长度限制。双：CA、高清 收稿日期：2010 年 11 月 12 日 IRG：ZAI1 SRC(99) 1. 项目标题（不超过 81 个字符，包括空格 a< 中非LeDEA 2. 对申请、计划公告或征集的具体请求的回应 Q 否 i ^ 是 （如果“是”，请注明编号和标题） 编号：RFA-AI-10-030 标题：评估艾滋病的国际流行病学数据库 (leDEA) 3. 项目总监/首席研究员 3a.姓名（姓氏、名字、中间名） 3b.度 3 小时。 eRA 共享用户名 阿纳斯托斯，凯瑟琳·玛丽医学博士卡纳斯托斯 3c.职位名称 3d.邮寄地址 fS^reef、城市、州、邮政编码） 医学、流行病学和人口健康教授 3311 Bainbridge Avenue 3e.部门、服务、实验室或同等部门 Bronx, NewYork 10467 医学系 3f.主要细分 流行病学和人口健康系 3克。电话和传真（区号、号码和分机号） 电子邮件地址： 电话：718-515-2593 传真：[e-mail] 人类受试者研究 4a。研究豁免 如果“是”，则豁免编号。 S 否 n 是 13 否 n 是 4b.联邦范围/^保险号 4c。临床试验4d。 NIH 定义的 III 期临床试验 ISI 否 D 是 Kl 否 n 是 5. 脊椎动物 S 否 D 是 5a。动物福利保证编号 拟议的初始费用期间的日期 8. 拟议的费用要求 支持（月、日、年—月/日/年） 预算期 支持期 从 到 7a。直接成本（美元） 7b．总成本（美元） 8a.直接成本 ($) 8b.总成本（美元） 2011 年 7 月 1 日 2016 年 6 月 30 日 $1,570,965 $1,999,581 $8,017,667 9997639 9. 申请组织 10. 组织类型 名称 阿尔伯特·爱因斯坦医学院 公立：-^ · 联邦 Q 州 · 地方 地址 ^ 300 Morris Park Avenue 私人：-> ^ 私人非营利组织 Bronx, NewYork 10461 营利性： -> CH 一般 CH 小型企业 I I 女性拥有的 CH 社会和经济弱势群体 11. 实体识别号码 113-1624225A2 邓白氏编号110521739 图标。区NY-007 12. 如果做出裁决，需通知行政官员 13. 申请组织的正式签字 姓名 Robert Ness 先生 姓名 Allen M. Spiegel，医学博士 头衔 补助金会计副主任 头衔 院长 地址 1300 Morris Park Avenue 地址 ^gQQ Morris Park Avenue, Bronx, NY 10461 纽约布朗克斯 10461-1602 电话：718 320 3712 传真：718 430 8675 邮箱：aorrn(gaecom.yu.edu 14. 申请组织的认证和接受：我证明 据我所知，本文中的陈述真实、完整和准确，并且 如果拨款，则接受遵守公共卫生服务条款和条件的义务 因该申请而被授予。我知道任何虚假、虚构或欺诈行为 陈述或主张可能会使我受到刑事、民事或行政处罚。 PHS 398（修订版 6/09）正面页面 电话：718 430 2801 传真：718 430 8122 电子邮件：[e-mail] 13 指定官员签名 日期 （墨水。“Per”signaturendtaccpdtable。） 表格第1页 仅在准备具有多个 PD/PL 的应用程序时使用。有关详细信息，请参阅http://qrants.nih.qov/qrants/multi pi/index.htm。 联系项目总监/首席研究员（姓、名、中）：Ana St OS、K athry n Mary 3. 项目总监/首席研究员 3a.姓名（姓氏、名字、中间名） 胡佛，唐纳德·R. 3c.职位名称 教授 硒。部门、服务、实验室或同等部门 统计学和生物统计学 3f.主要细分 健康、医疗保健政策和老龄化研究所 3克。电话和传真（区号、号码和分机号） 电话：732-445-2690 传真：732-445-3428 3. 项目总监/首席研究员 3a.姓名（姓氏、名字、中间名） 3c.职位名称 3e.部门、服务、实验室或同等部门 3f.主要细分 3克。电话和传真（区号、号码和分机号） 电话： 传真： 3. 项目总监/首席研究员 3a.姓名（姓氏、名字、中间名） 3c.职位名称 3e.部门、服务、实验室或同等部门 3f.主要细分 3克。电话和传真（区号、号码和分机号） 电话： 传真： 3. 项目总监/首席研究员 3a.姓名（姓氏、名字、中间名） 3c.职位名称 3e.部门、服务、实验室或同等部门 3f.主要细分 3克。电话和传真（区号、号码和分机号） 电话： 传真： PHS 398（修订版 6/09） 面部 3b.度 3 小时。 NIH 共享用户名 博士 MPH 博士 3d.邮寄地址（^Sfreef、城市、州、邮政编码） 弗里林海森路110号1107室 新泽西州新不伦瑞克省 电子邮件： [e-mail] 3b.学位 3d.邮寄地址 电子邮件： 3b.学位 3d.邮寄地址 电子邮件： 3b.学位 3d.邮寄地址 电子邮件： 续页 3小时。 NIH 共享用户名 （街道、城市、州、邮政编码） 3小时。 NIH 共享用户名 （街道、城市、州、邮政编码） ·-· 3小时。 NIH 共享用户名 （^Sfreef、城市、州、邮政编码） 表格第 1 页-续 项目总监/首席研究员（最后、第一、中间）：Ana St OS、K athry n Mary 项目摘要（参见说明）： 抗逆转录病毒疗法 (ART) 为数百万人带来新健康的承诺现已实现 非洲人。随着艾滋病毒护理和治疗计划在整个非洲实施，仔细监测其情况 有效性至关重要，这样护理和治疗资源才能得到最佳配置 益处。对 ART 的免疫学和临床反应、护理保留和行为成分（例如， 治疗依从性）需要阐明并定义生存的预测因素。艾滋病毒和抗逆转录病毒治疗的影响 非洲癌症的相关性基本上未被描述，并且与主要环境合并症的相互作用，例如 人们对疟疾知之甚少。我们提出了一个新的中非 LeDEA (CA-leDEA)，旨在优化 提高科学生产力和快速、高影响力的出版物；我们将 1.) 编译和管理 通过 a.) 从现有数据中提取大量患者的二级来源患者级数据 电子数据，或 b.) 新的现场系统，用于在资源匮乏的临床中有效捕获临床数据 设置; 2.) 开发创造性且灵活的科学流程，促进多种分析的高通量 数据来回答流行病学、操作和其他与艾滋病毒相关的研究问题，最终产生高 影响力出版物； 3.) 培养独立研究、数据管理、分析和分析的能力 五到十年内在每个中非国家出版，确保 CA- LEDEA。我们的团队在研究生产力和运营成功领域拥有悠久的历史 作为支持研究的创新 IT 开发，通过互补的技能和经验来优化 CA-leDEA 的活动。我们的四个合作伙伴是艾滋病毒护理服务的实施者（即政府） 第五个合作伙伴WE-ACTx卢旺达带来患者数量、研究经验和特殊资源 调查艾滋病恶性肿瘤。我们将开发行政和数据管理基础设施 支持流行病学和实施科学的实施，以回答以下关键问题 资源匮乏地区的艾滋病毒护理和治疗，由美国、喀麦隆和印度的综合研究团队提供 卢旺达。 相关性（参见说明）： 撒哈拉以南非洲地区是全球艾滋病毒疾病负担最重的地区。研究定义临床和 需要治疗成功的流行病学预测因子来指导临床医生护理艾滋病毒感染者。在 此外，实施科学可以指导政策制定者和方案实施者提供服务 提供最有效利用治疗资源并最大程度地提高公众健康的机制。